Benjamin Edwards Inc. Has $77.83 Million Stock Position in AbbVie Inc. $ABBV

Key Points

• Benjamin Edwards Inc. decreased its stake in AbbVie by 11.9% to 340,543 shares valued at $77.826 million, making AbbVie its 14th largest holding (0.9% of the portfolio).
• AbbVie beat Q1 estimates (EPS $2.65 vs. $2.59) and raised its 2026 outlook, with revenue up 12.4% year‑over‑year as immunology drugs helped offset Humira declines.
• Analysts are broadly positive with a consensus rating of "Moderate Buy" and a consensus target price of $252.90, accompanied by several recent price‑target hikes and upgrades.

Benjamin Edwards Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 340,543 shares of the company's stock after selling 45,929 shares during the period. AbbVie makes up 0.9% of Benjamin Edwards Inc.'s portfolio, making the stock its 14th largest holding. Benjamin Edwards Inc.'s holdings in AbbVie were worth $77,826,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Centennial Wealth Advisory LLC grew its stake in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock worth $484,000 after acquiring an additional 45 shares during the last quarter. Weil Company Inc. boosted its stake in AbbVie by 2.3% during the third quarter. Weil Company Inc. now owns 2,026 shares of the company's stock worth $469,000 after buying an additional 46 shares in the last quarter. Hardin Capital Partners LLC boosted its stake in AbbVie by 1.4% during the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company's stock worth $759,000 after buying an additional 46 shares in the last quarter. Inlet Private Wealth LLC boosted its stake in AbbVie by 0.3% during the third quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company's stock worth $3,937,000 after buying an additional 47 shares in the last quarter. Finally, D.B. Root & Company LLC boosted its stake in AbbVie by 4.3% during the third quarter. D.B. Root & Company LLC now owns 1,152 shares of the company's stock worth $267,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ABBV shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $240.00 price target on shares of AbbVie in a research note on Thursday. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target on the stock. UBS Group decreased their price target on shares of AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research note on Thursday, February 5th. Piper Sandler decreased their price target on shares of AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research note on Thursday, April 23rd. Finally, Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $252.90.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company's stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $206.63 on Friday. The stock has a market cap of $365.36 billion, a PE ratio of 101.79, a PEG ratio of 0.76 and a beta of 0.38. The business has a fifty day moving average of $214.55 and a two-hundred day moving average of $221.60. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analysts' expectations of $14.72 billion. During the same period last year, the business earned $2.46 earnings per share. The business's revenue was up 12.4% on a year-over-year basis. Analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's payout ratio is currently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.